谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.

Francesca Arezzo,Gaia Giannone,Daniele Castaldo,Giulia Scotto,Valentina Tuninetti,Margherita Turinetto,Michele Bartoletti,Serafina Mammoliti,Grazia Artioli,Giorgia Mangili,Vanda Salutari,Domenica Lorusso,Gennaro Cormio,Vera Loizzi,Claudio Zamagni,Antonella Savarese,Massimo Di Maio,Graziana Ronzino,Carmela Pisano,Sandro Pignata,Giorgio Valabrega

Frontiers in Oncology（2024）

引用 0|浏览23
暂无评分
摘要
[This corrects the article DOI: 10.3389/fonc.2023.1247291.].
更多
查看译文
关键词
endometrial cancer,molecular classification,immune checkpoint inhibitors,dostarlimab,pembrolizumab plus lenvatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要